Purpose: Prognosis of dental implant therapy after placement is commonly dependent on the efficient bonding
of titanium implant and jaw bone. Simvastatin (
SIM
), which is a classic antihyperlipidemic drug, has been
remarkably attracted in dental region since it was reported that
SIM
has bone regeneration effect, and thus,
SIM
has been expected as the compound to support dental implant therapy. In this study, we aimed for the
development of simvastatin-loaded gelatin/hydroxyapatite spherical granules (
SIM
/GE/HAP) using spheronizer
(Marumerizer) for efficient dental implant therapy.
Methods: Preparation of
SIM
/GE/HAP:
SIM
/GE/HAP was prepared using spheronizer for producing on a large
scale. Characterization of
SIM
/GE/HAP: The surface morphology of the
SIM
/GE/HAP was visualized using a
scanning electron microscope. In vitro drug release in phosphate buffered saline (PBS) or simulated body fluid
(SBF): The
SIM
/GE/HAP was determined by UV-VIS spectrometer. To understand the mechanism of
SIM
release from the
SIM
/GE/HAP, the results of in vitro release profiles were fitted to a mathematical model.
The X-ray powder diffraction (XRD) profile of
SIM
/GE/HAP was measured by powder X-ray diffractometer to
evaluate the composition and crystallinity of the granules before and after in vitro release test.
Results: The
SIM
/GE/HAP in SBF exhibited sustainable release profile for 1 week. In contrast, the
SIM
/GE/
HAP in PBS released
SIM
approximately 60% within 1 week. These results mean that
SIM
/GE/HAP implanted
in the body can release
SIM
until the implant is attached with jaw bone. The XRD spectrum of
SIM
/GE/HAP
after the release test in SBF was characteristics of HAP. On the other hand, The XRD spectrum of
SIM
/GE/
HAP after the release test in PBS showed most parts of granule bulk did not transform into HAP.
Conclusion: The results showed that
SIM
/GE/HAP prepared using spheronizer could release
SIM
continuously
and has a potential to promote the local bone regeneration.
Keywords: Bone regeneration, Simvastatin, Hydroxy apatite, Drug delivery system, Controlled release
抄録全体を表示